EyePro MD is a softgel supplement that purportedly offers eye-health benefits related to its “super blend” of lutein, zeaxanthin, astaxanthin, and omega-3s.
Valensa International (Eustis, FL) announced that it has received a patent from the U.S. Patent and Trademark Office for its proprietary eye-health ingredient combination, EyePro MD. EyePro MD is a softgel supplement that purportedly offers eye-health benefits related to its “super blend” of lutein, zeaxanthin, astaxanthin, and omega-3 fatty acids from krill, algae, or perilla seed.
EyePro MD is produced through Valensa’s own supercritical CO2 purification process and O2 peroxidation blocker technology, says the company, and is formulated with its proprietary Zanthin astaxanthin, XanMax lutein plus zeaxanthin, perilla seed–derived ALA omega-3 fatty acids, and seed-based phospholipids. It can also add omega-3 fatty acids from krill and algae oil. In addition, the formula is zinc-free, non-GMO, organic, and contains no allergens. The company notes that several studies have previously been conducted on the benefits of carotenoids for eye health functions, as well as research on astaxanthin for treatment of eye fatigue and protection from blue light.
“We have designed a small softgel loaded with a potent combination of ingredients that can be absorbed efficiently to optimize eye health,” said John Minatelli, PhD, senior vice president of business development, Valensa, in a press release. “Now with the patent IP in place, distributors and manufacturers from the food and nutraceutical industry can include EyePro MD in their products knowing there’s nothing else like it on the market.”
The company recommends a daily dose of one EyePro capsule, or 250 mg, per day. EyePro MD was awarded Patent No. 9,610,313, and is available for distribution as a finished product or formulation under license.